...
首页> 外文期刊>Infectious disorders drug targets >Prevalence, Presentation and Outcome of Secondary Bloodstream Infections among COVID-19 Patients
【24h】

Prevalence, Presentation and Outcome of Secondary Bloodstream Infections among COVID-19 Patients

机译:Prevalence, Presentation and Outcome of Secondary Bloodstream Infections among COVID-19 Patients

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The higher mortality rate in COVID-19 patients is still a concern. Though some studies mention that elderly patients with co-morbidities are at higher risk of mortality, some others report uneventful outcomes in young patients even without co-morbidities. Secondary bacterial and fungal infections, especially with nosocomial pathogens are known to be associated with worse outcome in the ongoing pandemic as well as in the previous viral outbreaks. In such a scenario, the outcome of hospitalized COVID-19 patients can be improved by timely identification of secondary infections using appropriate biomarkers and by following appropriate infection control measures to prevent the spread of nosocomial pathogens. Objective: The study aims to find out the prevalence of bloodstream infections (BSI) among hospitalized COVID-19 patients and to analyze their laboratory markers and outcome by comparing them with those without BSI. Methods: In this descriptive cross-sectional study, the prevalence of secondary BSI was determined among the hospitalized COVID-19 patients by including 388 blood culture bottles collected from 293 patients, which were received in the microbiology lab within the study period. Results: The overall prevalence of BSI in COVID-19 patients was 39.5 (116/293), out of which 35.5 (104/293) infections were bacterial, and 4.1 (12/293) were fungal, while 8.9 (26/293) patients grew contaminants, and 51.5 (151/293) were sterile. Common causative agents of secondary BSI were found to be MDR Klebsiella pneumoniae (10.9) and Acinetobacter baumannii (8.8) followed by Candida species (4.1). Patients with co-morbidities like diabetes, hypertension and COPD were at higher risk of developing BSI with significantly higher levels of sepsis markers such as Creactive protein (CRP), procalcitonin, ferritin and Interleukin-6 (IL-6). The mortality rate was significantly higher (60.2) in patients with BSI compared to the group of patients without BSI. Conclusion: Our findings suggest the necessity of early diagnosis of the secondary infections using appropriate biomarkers and following proper infection control measures to prevent the spread of the nosocomial infections and improve the outcome of hospitalized COVID-19 patients.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号